. Author manuscript; available in PMC: 2019 Jul 23.

Published in final edited form as: Cancer Cell. 2018 Jun 11;33(6):1017–1032.e7. doi: 10.1016/j.ccell.2018.05.009

Table 1. Post-therapy 4PD1^hi and clinical benefit of pembrolizumab.

Hazard ratios (risk of death) for post-therapy 4PD1^hi% and 4PD1^hi fold reduction by the Cox regression model in advanced melanoma patients treated with pembrolizumab (Figure 4C).

Variable	n	Hazard Ratio	95% CI	Cox p value
4PD1^hi % (3 weeks post-therapy)	52 (24 deaths)	1.4	(1.16, 1.70)	.0005 ***
FoldChange in 4PD1^hi%	52 (24 deaths)	4.4	(1.03, 19.14)	.046 *

Table 1. Post-therapy 4PD1hi and clinical benefit of pembrolizumab.

Table 1. Post-therapy 4PD1^hi and clinical benefit of pembrolizumab.